|
End-of-day quote
Other stock markets
|
||
| - GBX | - |
|
| 12:14pm | GSK, Relation Therapeutics Collaborate on Human Cellular Data Project | MT |
| 11:07am | Goldman Sachs still cautious about GSK |  |
| Market Cap | 79.93B 106B 93.31B 87.09B 150B 10,171B 153B 1,033B 404B 5,033B 399B 390B 17,399B | P/E 2026 * |
13.2x | P/E 2027 * | 11.7x |
|---|---|---|---|---|---|
| Enterprise Value | 100B 133B 117B 109B 188B 12,751B 192B 1,295B 506B 6,310B 500B 489B 21,812B | EV / Sales 2026 * |
2.95x | EV / Sales 2027 * | 2.61x |
| Free-Float |
99.07% | Yield 2026 * |
3.47% | Yield 2027 * | 3.64% |
Last Transcript: GlaxoSmithKline plc
| Manager | Title | Age | Since |
|---|---|---|---|
Luke Miels
CEO | Chief Executive Officer | - | 01/01/2026 |
Julie Brown
DFI | Director of Finance/CFO | 64 | 01/05/2023 |
| Chief Tech/Sci/R&D Officer | - | 01/12/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
Luke Miels
BRD | Director/Board Member | - | 06/05/2026 |
Hal Barron
BRD | Director/Board Member | 64 | 01/01/2018 |
Jonathan Symonds
CHM | Chairman | 68 | 01/09/2019 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.87% | +4.04% | +58.60% | +163.92% | 1,079B | |
| -0.45% | +3.87% | +57.95% | +52.18% | 640B | |
| +0.04% | +3.95% | +37.69% | +74.54% | 465B | |
| -0.37% | +2.98% | +38.64% | +33.00% | 353B | |
| -0.18% | +1.21% | +35.97% | +41.87% | 301B | |
| -0.48% | +2.77% | +13.41% | +16.57% | 271B | |
| -0.31% | +4.71% | +3.20% | -38.58% | 228B | |
| -1.39% | +5.90% | +27.70% | +64.00% | 209B | |
| -1.18% | +1.83% | +16.20% | +72.69% | 165B | |
| Average | -0.57% | +4.83% | +32.15% | +53.36% | 412.19B | |
| Weighted average by Cap. | -0.55% | +4.86% | +41.81% | +78.24% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 33.99B 45.16B 39.68B 37.04B 63.63B 4,325B 65.2B 439B 172B 2,140B 170B 166B 7,399B | 35.62B 47.33B 41.58B 38.82B 66.68B 4,533B 68.33B 460B 180B 2,243B 178B 174B 7,754B |
| Net income | 6.14B 8.15B 7.17B 6.69B 11.49B 781B 11.77B 79.32B 31.02B 387B 30.62B 29.95B 1,336B | 6.96B 9.24B 8.12B 7.58B 13.03B 885B 13.35B 89.91B 35.16B 438B 34.71B 33.95B 1,515B |
| Net Debt | 20.27B 26.93B 23.67B 22.09B 37.95B 2,580B 38.89B 262B 102B 1,277B 101B 98.92B 4,413B | 13.18B 17.51B 15.39B 14.37B 24.68B 1,678B 25.29B 170B 66.62B 830B 65.76B 64.33B 2,870B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
